126 related articles for article (PubMed ID: 38909879)
1. The high-bone-mass phenotype of novel transgenic mice with LRP5 A241T mutation.
Wang X; Zhang H; Hu L; He J; Jiang Q; Ren L; Yu K; Fu M; Li Z; He Z; Zhu J; Wang Y; Jiang Z; Yang G
Bone; 2024 Jun; ():117172. PubMed ID: 38909879
[TBL] [Abstract][Full Text] [Related]
2. High bone mass in mice expressing a mutant LRP5 gene.
Babij P; Zhao W; Small C; Kharode Y; Yaworsky PJ; Bouxsein ML; Reddy PS; Bodine PV; Robinson JA; Bhat B; Marzolf J; Moran RA; Bex F
J Bone Miner Res; 2003 Jun; 18(6):960-74. PubMed ID: 12817748
[TBL] [Abstract][Full Text] [Related]
3. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.
Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG
Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757
[TBL] [Abstract][Full Text] [Related]
4. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
[TBL] [Abstract][Full Text] [Related]
5. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
[TBL] [Abstract][Full Text] [Related]
6. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
[TBL] [Abstract][Full Text] [Related]
7. Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia.
Niziolek PJ; Bullock W; Warman ML; Robling AG
PLoS One; 2015; 10(11):e0140775. PubMed ID: 26554834
[TBL] [Abstract][Full Text] [Related]
8. Gender specific LRP5 influences on trabecular bone structure and strength.
Dubrow SA; Hruby PM; Akhter MP
J Musculoskelet Neuronal Interact; 2007; 7(2):166-73. PubMed ID: 17627087
[TBL] [Abstract][Full Text] [Related]
9. Analysis of multiple bone responses to graded strains above functional levels, and to disuse, in mice in vivo show that the human Lrp5 G171V High Bone Mass mutation increases the osteogenic response to loading but that lack of Lrp5 activity reduces it.
Saxon LK; Jackson BF; Sugiyama T; Lanyon LE; Price JS
Bone; 2011 Aug; 49(2):184-93. PubMed ID: 21419885
[TBL] [Abstract][Full Text] [Related]
10. The LRP5 high-bone-mass mutation causes alveolar bone accrual with minor craniofacial alteration.
Turkkahraman H; Flanagan S; Zhu T; Bellido TM; Yuan X
J Periodontal Res; 2023 Aug; 58(4):723-732. PubMed ID: 37128744
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes.
Leanza G; Fontana F; Lee SY; Remedi MS; Schott C; Ferron M; Hamilton-Hall M; Alippe Y; Strollo R; Napoli N; Civitelli R
J Bone Miner Res; 2021 Jul; 36(7):1403-1415. PubMed ID: 33831261
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
Ferrari SL; Deutsch S; Antonarakis SE
Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
[TBL] [Abstract][Full Text] [Related]
13. Novel familial mutation of LRP5 causing high bone mass: Genetic analysis, clinical presentation, and characterization of bone matrix mineralization.
Roetzer KM; Uyanik G; Brehm A; Zwerina J; Zandieh S; Czech T; Roschger P; Misof BM; Klaushofer K
Bone; 2018 Feb; 107():154-160. PubMed ID: 29208525
[TBL] [Abstract][Full Text] [Related]
14. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
[TBL] [Abstract][Full Text] [Related]
15. Mechanotransduction in bone tissue: The A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner.
Niziolek PJ; Warman ML; Robling AG
Bone; 2012 Sep; 51(3):459-65. PubMed ID: 22750014
[TBL] [Abstract][Full Text] [Related]
16. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition.
Riddle RC; Diegel CR; Leslie JM; Van Koevering KK; Faugere MC; Clemens TL; Williams BO
PLoS One; 2013; 8(5):e63323. PubMed ID: 23675479
[TBL] [Abstract][Full Text] [Related]
17. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
[TBL] [Abstract][Full Text] [Related]
18. Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
Foer D; Zhu M; Cardone RL; Simpson C; Sullivan R; Nemiroff S; Lee G; Kibbey RG; Petersen KF; Insogna KL
Osteoporos Int; 2017 Jun; 28(6):2011-2017. PubMed ID: 28283687
[TBL] [Abstract][Full Text] [Related]
19. The high bone mass phenotype of Lrp5-mutant mice is not affected by megakaryocyte depletion.
Yorgan T; David JP; Amling M; Schinke T
Biochem Biophys Res Commun; 2018 Mar; 497(2):659-666. PubMed ID: 29454962
[TBL] [Abstract][Full Text] [Related]
20. Normal hematopoiesis and lack of β-catenin activation in osteoblasts of patients and mice harboring Lrp5 gain-of-function mutations.
Galán-Díez M; Isa A; Ponzetti M; Nielsen MF; Kassem M; Kousteni S
Biochim Biophys Acta; 2016 Mar; 1863(3):490-498. PubMed ID: 26681532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
